1. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/vector-borne-diseases. 2024 [cited 2025 Oct 12]. Vector-borne diseases. Available from: https://www.who.int/
news-room/fact-sheets/detail/vector-borne-diseases
2. Reeves WC. Partners: serendipity in arbovirus research. J Vector Ecol. 2001;26(1):1–6.
3. Simmonds P, Becher P, Bukh J, Gould EA, Meyers G, Monath T, et al. ICTV Virus Taxonomy Profile: Flaviviridae. Journal of General Virology. 2017;98(1):2–3.
4. Firth AE, Atkins JF. A conserved predicted pseudoknot in the NS2A-encoding sequence of West Nile and Japanese encephalitis flaviviruses suggests NS1’ may derive from ribosomal frames-
hifting. Virol J. 2009;6(1):14.
5. Melian EB, Hinzman E, Nagasaki T, Firth AE, Wills NM, Nouwens AS, et al. NS1⁺ of Flaviviruses in the Japanese Encephalitis Virus Serogroup Is a Product of Ribosomal Frameshifting and
Plays a Role in Viral Neuroinvasiveness. J Virol. 2010;84(3):1641–7.
6. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/west-nile-virus. 2017 [cited 2025 Oct 14]. West Nile virus. Available from: https://www.who.int/news-room/
fact-sheets/detail/west-nile-virus
7. Ergünay K, Polat C, Özkul A. Vector-borne viruses in Turkey: A systematic review and bibliography. Antiviral Res. 2020;183:104934.
8. Pierson TC, Diamond MS. The continued threat of emerging flaviviruses. Nat Microbiol. 2020;5(6):796–812.
9. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue. 2025 [cited 2025 Oct 13]. Dengue. Available from: https://www.who.int/news-room/
fact-sheets/detail/dengue-and-severe-dengue
10. Lim A, Shearer FM, Sewalk K, Pigott DM, Clarke J, Ghouse A, et al. The overlapping global distribution of dengue, chikungunya, Zika and yellow fever. Nat Commun. 2025;16(1):3418.
11. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. Türkiye Zoonotik Hastalıklar Eylem Planı (2019-2023). 1st ed. Doğanay M, Şahin M TS, editor. Ankara: Artı6 Medya Tanıtım Matbaa
Ltd. Şti; 2019.
12. Nwaiwu AU, Musekiwa A, Tamuzi JL, Sambala EZ, Nyasulu PS. The incidence and mortality of yellow fever in Africa: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):1089.
13. Dick GWA, Kitchen SF, Haddow AJ. Zika Virus (I). Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952;46(5):509–20.
14. Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika Virus. New England Journal of Medicine. 2016;374(16):1552–63.
15. Weaver SC, Costa F, Garcia-Blanco MA, Ko AI, Ribeiro GS, Saade G, et al. Zika virus: History, emergence, biology, and prospects for control. Antiviral Res. 2016;130:69–80.
16. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/zika-virus. 2022 [cited 2025 Oct 14]. Zika virus. Available from: https://www.who.int/news-room/fact-sheets/
detail/zika-virus
17. Musso D, Ko AI, Baud D. Zika Virus Infection — After the Pandemic. New England Journal of Medicine. 2019;381(15):1444–57.
18. Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol. 2011;11(8):532–43.
19. Beatty PR, Puerta-Guardo H, Killingbeck SS, Glasner DR, Hopkins K, Harris E. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination.
Sci Transl Med. 2015;7(304).
20. Monath TP, Vasconcelos PFC. Yellow fever. Journal of Clinical Virology. 2015;64:160–73.
21. Miner JJ, Diamond MS. Zika Virus Pathogenesis and Tissue Tropism. Cell Host Microbe. 2017;21(2):134–42.
22. Joguet G, Mansuy JM, Matusali G, Hamdi S, Walschaerts M, Pavili L, et al. Effect of acute Zika virus infection on sperm and virus clearance in body fluids: a prospective observational study.
Lancet Infect Dis. 2017;17(11):1200–8.
23. Counotte MJ, Kim CR, Wang J, Bernstein K, Deal CD, Broutet NJN, et al. Sexual transmission of Zika virus and other flaviviruses: A living systematic review. PLoS Med. 2018;15(7):e1002611.
24. Maximova OA, Pletnev AG. Flaviviruses and the Central Nervous System: Revisiting Neuropathological Concepts. Annu Rev Virol. 2018;5(1):255–72.
25. Ludlow M, Kortekaas J, Herden C, Hoffmann B, Tappe D, Trebst C, et al. Neurotropic virus infections as the cause of immediate and delayed neuropathology. Acta Neuropathol.
2016;131(2):159–84.
26. Platt DJ, Smith AM, Arora N, Diamond MS, Coyne CB, Miner JJ. Zika virus–related neurotropic flaviviruses infect human placental explants and cause fetal demise in mice. Sci Transl Med.
2018;10(426).
27. Gaunt MW, Sall AA, Lamballerie X de, Falconar AKI, Dzhivanian TI, Gould EA. Phylogenetic relationships of flaviviruses correlate with their epidemiology, disease association and biogeog-
raphy. Journal of General Virology. 2001;82(8):1867–76.
28. Nelson AN, Ploss A. Emerging mosquito-borne flaviviruses. mBio. 2024;15(12).
29. Li H, Saucedo-Cuevas L, Shresta S, Gleeson JG. The Neurobiology of Zika Virus. Neuron. 2016;92(5):949–58.
30. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/yellow-fever. 2023 [cited 2025 Oct 13]. Yellow fever. Available from: https://www.who.int/news-room/fa-
ct-sheets/detail/yellow-fever
31. Uhuami AO, Lawal N, Bello MB, Imam MU. Flavivirus cross-reactivity: Insights into e-protein conservancy, pre-existing immunity, and co-infection. The Microbe. 2024; 4:100105.
32. Adebanjo T, Godfred-Cato S, Viens L, Fischer M, Staples JE, Kuhnert-Tallman W, et al. Update: Interim Guidance for the Diagnosis, Evaluation, and Management of Infants with Possible
Congenital Zika Virus Infection — United States, October 2017. MMWR Morb Mortal Wkly Rep. 2017;66(41):1089–99.
33. Rice ME, Galang RR, Roth NM, Ellington SR, Moore CA, Valencia-Prado M, et al. Vital Signs: Zika-Associated Birth Defects and Neurodevelopmental Abnormalities Possibly Associated with
Congenital Zika Virus Infection — U.S. Territories and Freely Associated States, 2018. MMWR Morb Mortal Wkly Rep. 2018;67(31).
34. Polat C. Enfeksiyon Kaynağı Vektörlerden Korunma. ANKEM Dergisi. 2025;39(1):22–8.
35. World Health Organization. Pesticides and their application for the control of vectors and pests of public health importance. 6th ed. 2006.
36. Moretti R, Lim JT, Ferreira AGA, Ponti L, Giovanetti M, Yi CJ, et al. Exploiting Wolbachia as a Tool for Mosquito-Borne Disease Control: Pursuing Efficacy, Safety, and Sustainability. Pat-
hogens. 2025;14(3):285.
37. Kean J, Rainey S, McFarlane M, Donald C, Schnettler E, Kohl A, et al. Fighting Arbovirus Transmission: Natural and Engineered Control of Vector Competence in Aedes Mosquitoes. Insects.
2015;6(1):236–78.
38. Pimentel AC, Cesar CS, Martins M, Cogni R. The Antiviral Effects of the Symbiont Bacteria Wolbachia in Insects. Front Immunol. 2021;11.
39. Velez ID, Uribe A, Barajas J, Uribe S, Ángel S, Suaza-Vasco JD, et al. Large-scale releases and establishment of wMel Wolbachia in Aedes aegypti mosquitoes throughout the Cities of Bello,
Medellín and Itagüí, Colombia. PLoS Negl Trop Dis. 2023;17(11):e0011642.
40. Yen PS, Failloux AB. A Review: Wolbachia-Based Population Replacement for Mosquito Control Shares Common Points with Genetically Modified Control Approaches. Pathogens.
2020;9(5):404.
41. Bourtzis K, Dobson SL, Xi Z, Rasgon JL, Calvitti M, Moreira LA, et al. Harnessing mosquito–Wolbachia symbiosis for vector and disease control. Acta Trop. 2014;132:S150–63.
42. Thomas S, Verma J, Woolfit M, O’Neill SL. Wolbachia-mediated virus blocking in mosquito cells is dependent on XRN1-mediated viral RNA degradation and influenced by viral replication
rate. PLoS Pathog. 2018;14(3):e1006879.
43. Center for Disease Control and Prevention. https://www.cdc.gov/dengue/vaccine/index.html. 2025 [cited 2025 Oct 15]. About a Dengue Vaccine. Available from: https://www.cdc.gov/den-
gue/vaccine/index.html
44. World Health Organization. https://www.who.int/news-room/questions-and-answers/item/dengue-vaccines. 2025 [cited 2025 Oct 15]. Vaccines and immunization: Dengue. Available from:
https://www.who.int/news-room/questions-and-answers/item/dengue-vaccines
45. Alkan C, Bichaud L, de Lamballerie X, Alten B, Gould EA, Charrel RN. Sandfly-borne phleboviruses of Eurasia and Africa: Epidemiology, genetic diversity, geographic range, control measu-
res. Antiviral Res. 2013;100(1):54–74.
46. Ergunay K, Ayhan N, Charrel RN. Novel and emergent sandfly‐borne phleboviruses in Asia Minor: a systematic review. Rev Med Virol. 2017;27(2).
47. Sellali S, Lafri I, Garni R, Manseur H, Besbaci M, Lafri M, et al. Epidemiology of Sandfly-Borne Phleboviruses in North Africa: An Overview. Insects. 2024;15(11):846.
48. Polat C, Ayhan N, Saygan MB, Karahan S, Charrel R, Ergünay K. Comprehensive Cross-Sectional Evaluation of Human Sandfly-Borne Phlebovirus Exposure in an Endemic Region. Viruses.
2023;15(9):1902.
49. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/rift-valley-fever. 2024 [cited 2025 Oct 19]. Rift Valley fever. Available from: https://www.who.int/news-room/
fact-sheets/detail/rift-valley-fever
50. Wright D, Kortekaas J, Bowden TA, Warimwe GM. Rift Valley fever: biology and epidemiology. Journal of General Virology. 2019;100(8):1187–99.
51. Casel MA, Park SJ, Choi YK. Severe fever with thrombocytopenia syndrome virus: emerging novel phlebovirus and their control strategy. Exp Mol Med. 2021;53(5):713–22.
52. Cetin H, Ozbel Y. Sandflies and Their Control Methods. Turkish Journal of Parasitology. 2017;41(2):102–13.
53. World Health Organization. Pesticides and their application : for the control of vectors and pests of public health importance [Internet]. 6th ed. 2006 [cited 2025 Oct 17]. Available from:
https://www.who.int/publications/i/item/who-cds-ntd-whopes-gcdpp-2006.1
54. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/chikungunya. 2025 [cited 2025 Oct 13]. Chikungunya. Available from: https://www.who.int/news-room/
fact-sheets/detail/chikungunya
55. Chen R, Mukhopadhyay S, Merits A, Bolling B, Nasar F, Coffey LL, et al. ICTV Virus Taxonomy Profile: Togaviridae. Journal of General Virology. 2018;99(6):761–2.
56. Ribeiro dos Santos G, Jawed F, Mukandavire C, Deol A, Scarponi D, Mboera LEG, et al. Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns. Nat
Med. 2025;31(7):2342–9.
57. de Souza WM, Lecuit M, Weaver SC. Chikungunya virus and other emerging arthritogenic alphaviruses. Nat Rev Microbiol. 2025;23(9):585–601.
58. Us AD, Ergunay K. Viral zoonozlar. In: Us AD, Ergunay K, editors. Molekuler, Klinik ve Tanisal Viroloji. Ankara: Bilimsel Tip Yayinevi; 2012.
59. Freppel W, Silva LA, Stapleford KA, Herrero LJ. Pathogenicity and virulence of chikungunya virus. Virulence. 2024;15(1).
60. Centers for Disease Control and Prevention. https://www.cdc.gov/chikungunya/hcp/diagnosis-testing/index.html. 2024 [cited 2025 Oct 19]. Clinical Testing and Diagnosis for Chikungunya
Virus Disease. Available from: https://www.cdc.gov/chikungunya/hcp/diagnosis-testing/index.html
61. U.S. Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-update-safety-ixchiq-chikungunya-vaccine-live. 2025 [cited 2025 Oct
15]. FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-update-safety-ixchiq-c-
hikungunya-vaccine-live
62. Bennett SR, McCarty JM, Ramanathan R, Mendy J, Richardson JS, Smith J, et al. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like
particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. Lancet Infect Dis. 2022;22(9):1343–55.
63. Kuhn JH, Alkhovsky S V., Avšič-Županc T, Bergeron É, Burt F, Ergünay K, et al. ICTV Virus Taxonomy Profile: Nairoviridae 2024. Journal of General Virology. 2024;105(4).
64. Ergünay K, Polat C, Özkul A. Vector-borne viruses in Turkey: A systematic review and bibliography. Antiviral Res. 2020;183.
65. T.C. Sağlık Bakanlığı HSGM. Kırım Kongo kanamalı ateşi. In: Doğanay M, Şahin M, Topluoğlu S, editors. Türkiye Zoonotik Hastalıklar Eylem Planı (2019-2023). Ankara: Artı6 Medya Tanı-
tım Matbaa Ltd. Şti.; 2019. p. 81–96.
66. Frank MG, Weaver G, Raabe V. Crimean Congo Hemorrhagic Fever Virus for Clinicians—Virology, Pathogenesis, and Pathology. Emerg Infect Dis. 2024;30(5).
67. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/crimean-congo-haemorrhagic-fever#:~:text=Crimean%2DCongo%20haemorrhagic%20fever%20
(CCHF)%20is%20a%20widespread%20disease,rate%20of%2010%E2%80%9340%25. 2025 [cited 2025 Oct 20]. Crimean-Congo haemorrhagic fever. Available from: https://www.who.int/
news-room/fact-sheets/detail/crimean-congo-haemorrhagic-fever#:~:text=Crimean%2DCongo%20haemorrhagic%20fever%20(CCHF)%20is%20a%20widespread%20disease,rate%20
of%2010%E2%80%9340%25
68. Crimean-Congo haemorrhagic fever. Available from: World Health Organization. https://www.who.int/news-room/fact-sheets/detail/crimean-congo-haemorrhagic-fever [cited 2025 Oct
19].
69. Connelly CR, Gimnig JE. Mosquitoes, Ticks, and Other Arthropods. In: CDC Yellow Book 2026: Health Information for International Travel [Internet]. 2025 [cited 2025 Oct 19]. Available
from: https://www.cdc.gov/yellow-book/hcp/environmental-hazards-risks/mosquitoes-ticks-and-other-arthropods.html
70. Mascarin GM, Lopes RB, Delalibera Í, Fernandes ÉKK, Luz C, Faria M. Current status and perspectives of fungal entomopathogens used for microbial control of arthropod pests in Brazil. J
Invertebr Pathol. 2019; 165:46–53.
71. Sullivan CF, Parker BL, Skinner M. A Review of Commercial Metarhizium- and Beauveria-Based Biopesticides for the Biological Control of Ticks in the USA. Insects. 2022;13(3):260.
72. Marciano AF, Mascarin GM, Franco RFF, Golo PS, Jaronski ST, Fernandes ÉKK, et al. Innovative granular formulation of Metarhizium robertsii microsclerotia and blastospores for cattle tick
control. Sci Rep. 2021;11(1):4972.
73. Makwarela TG, Seoraj-Pillai N, Nangammbi TC. Tick Control Strategies: Critical Insights into Chemical, Biological, Physical, and Integrated Approaches for Effective Hard Tick Management.
Vet Sci. 2025;12(2):114